MDXH · MDxHealth
AI read · Neutral
The AI's read
MDxHealth reported 14% sequential revenue growth to $27.2M, eliminated a $10.4M contingent liability, completed the Resolve UTI transition, and raised $20M. These moves improve liquidity and clean the balance sheet but adjusted EBITDA stayed negative $2.3M. Management reiterated $110–$115M revenue guidance. The stock has already jumped ~29.7%, so much of the upside looks priced in. Operational fixes matter, but sustainable profit improvement is the real test. We lean neutral because the big intraday move compresses upside while execution risk remains.